Skip to content

Celcuity CELC Total Current Liabilities

Total Current Liabilities at other companies

Eli Lilly logo
Eli LillyLLY
$36.63B+21.8%
Gilead Sciences logo
Gilead SciencesGILD
$9.48B-23.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$816.37M+437%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$29.75M-19.7%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$57.98M+17.6%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$14.33M-60.1%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's total current liabilities?
Celcuity (CELC) reported total current liabilities of $33.21M in Q1 2026.
How has Celcuity's total current liabilities changed year-over-year?
Celcuity's total current liabilities increased by 0.9% year-over-year, from $32.92M to $33.21M.
What is the long-term trend for Celcuity's total current liabilities?
Over 5 years (2020 to 2025), Celcuity's total current liabilities has grown at a 106.2% compound annual growth rate (CAGR), from $1.19M to $44.15M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.